A sweeping overhaul of the Vaccine Injury Compensation Program pits Health Secretary Robert F. Kennedy Jr.’s skepticism against long-standing public health protections, raising risks of destabilizing vaccine supply and public confidence.
At a Glance
- Kennedy has declared the Vaccine Injury Compensation Program (VICP) “broken” and pledged substantial reforms.
- He plans to shift liability back toward manufacturers rather than having HHS act as defendant.
- A mass firing of 17 CDC ACIP members and their replacement with individuals linked to vaccine litigation has raised alarms.
- Experts warn that weakening liability protections could deter manufacturers or drive vaccine prices higher.
- Senate Democrats have launched an investigation into Kennedy’s overhaul of CDC advisory bodies.
Program Under Fire
In late July 2025, Kennedy, who became Health and Human Services Secretary in February, announced his intention to reform the National Vaccine Injury Compensation Program, established under the 1986 National Childhood Vaccine Injury Act. He described VICP as inefficient, unfairly structured, and not meeting Congress’s original intent.
Kennedy proposes that manufacturers—not HHS—should bear greater liability exposure, reversing decades of a no-fault system funded by a 75‑cent excise tax per vaccine dose. Public health experts warn these changes may discourage vaccine production or inflate prices, potentially reducing availability.
Watch now: RFK Jr. plans to reform vaccine program · YouTube
Advisory Overhaul Sparks Controversy
As part of his broader “Make America Healthy Again” agenda, Kennedy terminated all 17 members of the Advisory Committee on Immunization Practices (ACIP), the group whose guidance shapes vaccine coverage policy via Medicaid, insurers, and federal programs. He replaced them with seven appointees, including figures known for anti-vaccine advocacy and litigation history.
Critics, including former public‑health officials, argue this move undermines scientific rigor and public trust, potentially limiting vaccine access. A coalition of Senate Democrats has opened investigations into conflicts of interest and vetting protocols.
Legal and Market Implications
The VICP delivers compensation via a no-fault system overseen by the U.S. Court of Federal Claims. As of mid‑2023, it had awarded nearly $4.6 billion in settlements, with an average of ~1.2 awards per million doses administered.
Its design was intended to stabilize vaccine supply by limiting litigation against manufacturers. Kennedy’s proposed rollback of these protections challenges that balance, raising the prospect of renewed lawsuits and risk‑averse behavior by pharma firms.
Health Policy Fallout
Kennedy’s reforms have ignited sharp concern across sectors. Public health leaders warn that the dual strategy of advisory board disruption and compensation overhaul could reduce vaccine uptake and reignite outbreaks. Governments, clinicians, and insurers may have to fill the advisory gap if trust collapses.
Former COVID‑response coordinator Ashish Jha specifically condemned the chair replacement at ACIP as a move that “undermines vaccine recommendations” and threatens insurance-based vaccine access. He urged Congress and state health authorities to create independent advisory systems urgent to preserve immunization infrastructure.
Possible Paths Ahead
Kennedy’s reforms must pass through Congressional mandates, public comment, and legal review. The Senate’s current probe, combined with state‑level pushback and independent advisory coalitions, may blunt or modify his proposals. Yet, even proposed changes could signal new instability to vaccine makers and providers.
If liability protections shrink and advisory guidance shifts, vaccine pricing, availability, and uptake may all be affected—increasing the risk of outbreaks and eroding decades of public health gains.
